期刊文献+

影响颅内恶性肿瘤患者体内苯妥英钠血药浓度的相关因素

Associated Influential Factors of Blood Concentration of Phenytoin Sodium in Patients with Intracranial Malignant Tumor
原文传递
导出
摘要 目的:探讨苯妥英钠预防颅内恶性肿瘤患者手术后癫痫的血药浓度与其体内病理生理因素及合并用药的相关性,为临床合理使用苯妥英钠提供参考。方法:收集133例次颅内肿瘤患者手术后使用苯妥英钠预防癫痫的病历资料,记录患者性别、年龄、体质量、血药浓度、CYP2C9和CYP2C19基因多态性,以及相应生化检验值。应用SAS软件(6.04&8.0版)对数据进行多元线性回归分析。结果:苯妥英钠血药浓度与年龄和体质量之间存在明显正相关性(P<0.05),但与CYP2C9基因多态性呈明显负相关性(P<0.05)。结论:应主要从患者年龄、体质量以及CYP2C9基因多态性的角度,设计苯妥英钠的个体化剂量方案。 OBJECTIVE:To investigate the relation between blood concentration of phenytoin sodium and patho-physiological factors and drug combination in patients with intracranial malignant tumor after surgery,and to provide reference for rational use of phenytoin sodium in the clinic.METHODS:Blood concentration of phenytoin sodium and clinical information data such as gender,age,body weight,gene polymorphisms of CYP2C9 and CYP2C19,the corresponding biochemical testing results were collected from 133 patients with intracranial malignant tumor after surgery and analyzed with multiple linear regression method by using SAS software(6.04 & 8.0 edition).RESULTS:Significant positive relation was found between blood concentration of phenytoin sodium and age or body weight(P&lt;0.05),but significant negative relation was found between blood concentration of phenytoin sodium and gene polymorphisms of CYP2C9(P&lt;0.05).CONCLUSIONS:Individual dosage regimen may be designed according to patient’s age,body weight and gene polymorphisms of CYP2C9.
出处 《中国药房》 CAS CSCD 2013年第30期2824-2826,共3页 China Pharmacy
基金 首都医学发展科研基金资助(No.2009-2055)
关键词 苯妥英钠 血药浓度 多元线性回归 Phenytoin sodium Blood concentration Multiple linear regression
  • 相关文献

参考文献7

  • 1Temldn NR.Preventing and treating posttraumatic seizures: the human experience[J]. Epilepsia, 2009, 50 (Suppl 2) : 10. 被引量:1
  • 2Lee SY, Lee ST, Kim JW. Contributions of CYP2C9/ CYP2C19 genotypes and drug interaction to the phenyto- in treatment in the Korean epileptic patients in the clinical setting[J]. J Biochem Mol Biol, 2007,40 (3) : 448. 被引量:1
  • 3Horsmans Y, Van den Berge V, Bouckaert A, et al. Phe- nytoin hydroxylation in a healthy Caucasian population: bimodal distribution of hydroxyphenytoin urinary excre- tion[J]. Pharmacol Toxicol, 1997,81 (6) :276. 被引量:1
  • 4Hung CC, Lin C J, Chen CC, et al. Dosage recommenda- tion of phenytoin for patients with epilepsy with different CYP2Cg/CYP2C19 polymorphisms[J]. Ther Drug Monit, 2004,26(5) : 534. 被引量:1
  • 5黄越,杨静芳,齐晓涟,王育琴,王维治,陈彪.CYP2C19和CYP2C9基因型与苯妥英血药浓度关系的研究[J].中华医学杂志,2004,84(20):1686-1689. 被引量:17
  • 6Rosemary J, Surendiran A, Rajan S, et al. Influence of the CYP2C9 & CYP2C19 polymorphisms on phenytoin hydroxylation in healthy individuals from south India[J]. lndian J Med Res,2006,123( 5 ) :665. 被引量:1
  • 7Yukawa E, Mamiya K. Effect of CYP2C19 genetic poly- morphism on pharmacokinetics of phenytoin and pheno- barbital in Japanese epileptic patients using Non-linear Mixed Effects Model approach[J]. J Clin Pharm Ther, 2006,31(3) :275. 被引量:1

二级参考文献10

  • 1王维治.神经病学(第4版)[M].北京:人民卫生出版社,2002.149. 被引量:61
  • 2Yoon YR, Shon JH, Kim MK, et al. Frequency of cytochrome P450 2C9 mutant alleles in a Korean population. Br J Clin Pharmacol, 2001, 51: 277-280. 被引量:1
  • 3van der Weide J, Steijns LS, van Weelden MJ, et al. The effect of genetic polymorphism of cytochrome P450 CYP2C9 on phenytoin dose requirement. Pharmacogentics, 2001, 11: 287-291. 被引量:1
  • 4Shimamoto JI, Ieiri A, Urae M, et al. Lack of differences in diclofenac (a substrate for CYP2C9) pharmacokinetics in healthy volunteers with respect to the single CYP2C9*3 allele. Eur J Clin Pharmacol, 2000, 56: 65-68. 被引量:1
  • 5Ninomiya H, Mamiya K, Matsuo S, et al. Genetic polymorphism of the CYP2C subfamily and excessive serum phenytoin concentration with central nervous system intoxication. Ther Drug Monit, 2000, 22: 230-232. 被引量:1
  • 6Coutts RT, Urichuk LJ. Polymorphic cytochromes P450 and drugs used in psychiatry. Cell Mol Neurobiol, 1999, 19: 325-354. 被引量:1
  • 7de Morais SM, Wilkinson GR, Blaisdell J, et al. The major genetic defect responsible for the polymorphism of S-mephenytoin metabolism in humans. J Biol Chem, 1994, 269: 15419-15422. 被引量:1
  • 8de Morais SM, Wikinson GR, Blaisdell J, et al. Identification of a new genetic defect responsible for the polymorphism of (S)-mephenytoin metabolism in Japanese. Mol Pharmacol, 1994, 46: 594-598. 被引量:1
  • 9Imai J, Ieiri I, Mamiya K, et al. Polymorphism of the cytochrome P450(CYP) 2C9 gene in Japanese epilepsy patients: genetic analysis of the CYP2C9 locus. Pharmacogenetics, 2000, 10: 85-89. 被引量:1
  • 10Kristensen VN, Kelefiotis D, Kristensen T, et al. High-throughput methods for detection of genetic variation. Biotechniques, 2001, 30: 318-322, 324, 326. 被引量:1

共引文献16

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部